Browse studies

Find your next paid study

41 recruiting studies matching your filters

Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma

This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurren…

High Grade Astrocytic TumorRecurrent Glioblastoma, IDH-WildtypeRecurrent Gliosarcoma

Estimated

~$10 – $6,250

Mayo ClinicNCT05465954

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma: Study Protocol for An International Multicenter Prospective Cohort Study (ENCRAM 2302)

Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, …

GlioblastomaGlioblastoma MultiformeGlioblastoma, IDH-wildtype+5 more

Estimated

~$10 – $1,125

Jasper GerritsenNCT06283927

Observational

Exploration Into the Association Between Decorin (DCN) Expression and MR Phenotypes in GBM

This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be …

GlioblastomaRecurrent GlioblastomaResectable Glioblastoma

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT06090903

Phase 1

Clinical Trial of D2C7-IT + 2141-V11 Combination Immunotherapy Administered Via Convection Enhanced Delivery in Non-enhancing Tumor Post-resection of Recurrent Glioblastoma, Followed by Cervical Perilymphatic Subcutaneous Injections of 2141-V11

The purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with …

Recurrent Glioblastoma IDH Wildtype

Estimated

~$10 – $7,500

Darell BignerNCT06455605

Phase 1

Phase 1, Dose Escalation, Non-Randomized, Open Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells (AMSCs) for Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblas…

Recurrent Glioblastoma, IDH-WildtypeRecurrent Astrocytoma, IDH-Mutant, Grade 4Astrocytoma, Grade IV

Estimated

~$10 – $6,250

Mayo ClinicNCT05789394